医学
血压
内科学
肾脏疾病
糖尿病
肾功能
心脏病学
比例危险模型
指南
疾病
风险因素
心力衰竭
高血压前期
2型糖尿病
心率
风险评估
连续变量
阶段(地层学)
社区动脉粥样硬化风险
作者
Yuta Suzuki,Masachika Nishikawa,Hidehiro Kaneko,Akira Okada,Toshiyuki Ko,Katsuhito Fujiu,Norifumi Takeda,Hiroyuki Morita,Naoki Nakagawa,Tatsuhiko Azegami,Kaori Hayashi,Takashi Yokoo,Koichi Node,Hideo Yasunaga,Norihiko Takeda
标识
DOI:10.1038/s41440-026-02801-7
摘要
Abstract We investigated the association between blood pressure (BP) and the risk of cardiovascular disease (CVD) in individuals with non-proteinuric chronic kidney disease (CKD) without diabetes. Using a large-scale nationwide administrative claims and health checkup database in Japan, we identified 287,238 non-diabetic adults with an estimated glomerular filtration rate <60 mL/min/1.73 m 2 and negative/trace proteinuria. We examined the association between BP and CVD events by modeling BP both as a continuous variable and as a categorical variable according to the 2017 ACC/AHA guideline classification. The primary outcome was a composite of myocardial infarction, stroke, heart failure, and atrial fibrillation. Multivariable Cox regression analyses showed that higher systolic BP (SBP) was associated with increased CVD risk (hazard ratio [HR] 1.05 per 10 mmHg; 95% CI 1.04–1.05). Compared with normal BP, the HRs were 1.03 (95% CI 1.00–1.07) for elevated BP, 1.08 (1.05–1.11) for stage 1 hypertension, and 1.20 (1.17–1.24) for stage 2 hypertension. Restricted cubic spline analysis showed an increase in CVD risk at SBP levels above ~130 mmHg. However, among individuals receiving antihypertensive medication, a U-shaped association was observed, with an increased risk also evident at SBP levels below ~130 mmHg. In individuals with non-proteinuric CKD without diabetes, higher SBP was positively associated with increased cardiovascular risk. However, a U-shaped association observed among individuals receiving antihypertensive treatment suggests that the relationship between BP and cardiovascular risk may be complex in this population, highlighting the potential importance of individualized clinical assessment.
科研通智能强力驱动
Strongly Powered by AbleSci AI